Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection.

Delphine Planas; Isabelle Staropoli; Francoise Porrot; Florence Guivel-Benhassine; Lynda Handala; Matthieu Prot; William Henry Bolland; Julien Puech; Helene Pere; David Veyer; Aymeric Seve; Etienne Simon-Loriere; Timothee Bruel; thierry prazuck; Karl Stefic; Laurent Hocqueloux; Olivier Schwartz.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22277885

Documentos relacionados

  1. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
  2. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  3. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
  4. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
  5. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
  6. Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults.
  7. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron.
  8. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
  9. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
  10. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants.